Yazar "Alroughani, Raed" için listeleme

Toplam kayıt 6, listelenen: 1-6

Clinical and therapeutic predictors of disease outcomes in AQP4-IgG + neuromyelitis optica spectrum disorder

Kunchok, Amy; Malpas, Charles; Nytrova, Petra; Havrdova, Eva Kubala; Alroughani, Raed; Terzi, Murat; Oreja-Guevara, Celia (Elsevier Sci Ltd, 2020)

Background: Aquaporin-4-IgG positive (AQP4-IgG(+)) Neuromyelitis Optica Spectrum Disorder (NMOSD) is an uncommon central nervous system autoimmune disorder. Disease outcomes in AQP4-IgG + NMOSD are typically measured by ...
Clinical determinants and therapeutic modifiers of relapse and disability outcomes in neuromyelitis optica spectrum disorder

Kunchok, Amy; Malpas, Charles; Nytrova, Petra; Havrdova, Eva; Alroughani, Raed; Terzi, Murat; Oreja-Guevara, Celia (Lippincott Williams & Wilkins, 2019)

…
Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod

Fragoso, Yara Dadalti; Spelman, Tim; Boz, Cavit; Alroughani, Raed; Lugaresi, Alessandra; Vucic, Steve; Haartsen, Jodi (Elsevier Sci Ltd, 2018)

Background: Fingolimod is an efficient and safe drug for treating relapsing-remitting multiple sclerosis (RRMS). In vivo, fingolimod is phosphorylated and binds to "sphingosine-1-phosphate"(S1P) receptors that are expressed ...
Presentation of Neuromyelitis Optica (NMO) in patients from different racial groups: analysis of the global NMOBase Registry

Kister, Ilya; Bacon, Tamar; Shaygannejad, Vahid; Havrdova, Eva; Alroughani, Raed; Terzi, Murat; Castillo Trivino, Tamara (Lippincott Williams & Wilkins, 2018)

…
Prospectively tracking disease course and treatment changes in Neuromyelitis Optica using NMOBase, a global online registry.

Kister, Ilya; Bacon, Tamar; Shaygannejad, Vahid; Hor, Jyh Yung; Alroughani, Raed; Haas, Shannon; Devranis, Paschalis (Lippincott Williams & Wilkins, 2016)

…
Reply to: Comment on YD Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)]

Fragoso, Yara Dadalti; Brooks, Joseph Bruno B.; Spelman, Tim; Boz, Cavit; Alroughani, Raed; Lugaresi, Alessandra; Haartsen, Jodi (Elsevier Sci Ltd, 2018)

…

Yazar "Alroughani, Raed" için listeleme

Clinical and therapeutic predictors of disease outcomes in AQP4-IgG + neuromyelitis optica spectrum disorder ﻿

Clinical determinants and therapeutic modifiers of relapse and disability outcomes in neuromyelitis optica spectrum disorder ﻿

Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod ﻿

Presentation of Neuromyelitis Optica (NMO) in patients from different racial groups: analysis of the global NMOBase Registry ﻿

Prospectively tracking disease course and treatment changes in Neuromyelitis Optica using NMOBase, a global online registry. ﻿

Reply to: Comment on YD Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)] ﻿

Clinical and therapeutic predictors of disease outcomes in AQP4-IgG + neuromyelitis optica spectrum disorder

Clinical determinants and therapeutic modifiers of relapse and disability outcomes in neuromyelitis optica spectrum disorder

Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod

Presentation of Neuromyelitis Optica (NMO) in patients from different racial groups: analysis of the global NMOBase Registry

Prospectively tracking disease course and treatment changes in Neuromyelitis Optica using NMOBase, a global online registry.

Reply to: Comment on YD Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)]